- Home
- LDP vs IVVD Comparison
LDP vs IVVD Comparison
Compare LDP & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDP | IVVD |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.4M | 692.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LDP | IVVD |
|---|---|---|
| Price | $21.10 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 102.5K | ★ 5.2M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,039,000.00 |
| Revenue This Year | N/A | $103.88 |
| Revenue Next Year | N/A | $171.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 332.71 |
| 52 Week Low | $16.16 | $0.35 |
| 52 Week High | $20.30 | $3.07 |
Technical Indicators
Market Signals| Indicator | LDP | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 38.75 | 59.43 |
| Support Level | $21.16 | $2.52 |
| Resistance Level | $21.35 | $3.01 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 5.81 | 60.23 |
Price Performance
Historical ComparisonAbout LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.